GENE

Genetic Technologies Ltd

Genetic Technologies Ltd (GENE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -2.4
Rev Growth YoY -10.6%
Gross Margin 61.1%
Price Return 3M 5.0%
Price Return 12M 18.6%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.4
ROE -185.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.2) B- (2.9) C (2.4) C- (1.9) C (2.4)
2026-08-04 C+ (2.7) C (2.2) B- (2.9) C (2.4) C- (1.9) C (2.4)
2026-08-03 C+ (2.7) C (2.3) B- (3.0) C (2.4) C- (2.0) C (2.5)
2026-08-02 C+ (2.7) C (2.3) B- (3.0) C (2.4) C- (1.9) C (2.5)